Varenicline + PSF-M for Smoking Cessation in HIV/AIDS

Recruiting at3 trial locations

Overseen by Gina Kruse, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Recruiting

Sponsor: Massachusetts General Hospital

Must be taking: Varenicline

Must not be taking: Antipsychotics

Disqualifiers: Pregnancy, Breastfeeding, Liver failure, others

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests a mobile app and a medication to help people with HIV quit smoking. The app provides tips and support, while the medication reduces cravings. The study aims to see if this combination is more effective than standard care.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, you must be able to use varenicline safely, which will be evaluated by your primary provider.

What data supports the effectiveness of the drug Varenicline for smoking cessation in people living with HIV/AIDS?

Research shows that Varenicline is effective for helping people with HIV quit smoking, with a 42% abstinence rate in one study. It also does not negatively impact HIV treatment and may improve psychological well-being, such as reducing depression and anxiety. ^{1 2 3 4 5}

Is the combination of Varenicline and PSF-M safe for smoking cessation in people with HIV/AIDS?

Varenicline, used for smoking cessation, has been studied in people with HIV and is generally considered safe, though common side effects include nausea and sleep disturbances. Serious side effects are rare, but monitoring for changes in mood or behavior is recommended. In studies, it did not negatively affect HIV treatment outcomes. ^{2 5 6 7 8}

How is the drug varenicline unique for smoking cessation in people with HIV/AIDS?

Varenicline is unique for smoking cessation in people with HIV/AIDS because it has been specifically studied for safety and effectiveness in this population, showing it can help reduce smoking without negatively affecting HIV treatment outcomes. It works by reducing nicotine withdrawal symptoms and cravings, and it has been found to be more effective than some other smoking cessation aids like bupropion. ^{1 2 5 6 9}

Research Team

Gina Kruse, MD

Principal Investigator

University of Colorado, Denver

Eligibility Criteria

This trial is for adults over 18 with HIV who smoke tobacco, have a viral load under 1000 copies/mL, and CD4 count above 200 cells/mm3. They must read at a 6th-grade level in Tamil, Telugu or English and can safely use varenicline. Women must agree to contraception during the study.

Inclusion Criteria

You have recently been diagnosed with HIV, your viral load is below 1000 copies/mL and your CD4 count is above 200 cells/mm3.

I am 18 years old or older.

You are a current smoker or dual tobacco user, confirmed by exhaled carbon monoxide of 7 parts per million or higher.

Exclusion Criteria

I have had a heart attack or unstable chest pain in the last 30 days.

My liver enzymes are high or my kidney function is low.

I have a history of psychosis or am taking anti-psychotic medications.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive Varenicline and Positively Smoke Free-Mobile intervention

12 weeks

Multiple visits (in-person and virtual)

Follow-up

Participants are monitored for tobacco abstinence and safety

12 weeks

2 visits (in-person)

Treatment Details

Interventions

• Positively Smoke Free Mobile (PSF-M) (Behavioral Intervention)
• Standard Care (Behavioral Intervention)
• Varenicline (Nicotinic Acetylcholine Receptor Partial Agonist)

Trial Overview The study tests an intervention to help people with HIV quit smoking using PSF-M (a mobile behavioral program) and Varenicline (a medication). Participants will receive either this combination or standard care to see which helps more with quitting.

Participant Groups

Group I: Varenicline + Positively Smoke Free - Mobile Experimental Treatment 2 Interventions

Offer of varenicline per package dosing with dose escalation over week 1: 0.5 mg once daily on days 1 - 3, 0.5 mg twice daily on days 4 -7, followed by 1.0 mg twice daily on days 8 to 84. Offer of Positively Smoke Free Mobile delivered by mobile phone including 42 days of content, tailored to individual quit date.

Group II: Standard Care Active Control 1 Intervention

Brief advice to quit tobacco Offer of referral to the national tobacco quitline

Varenicline is already approved in Canada for the following indications:

Approved in Canada as Champix for:

• Smoking cessation

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials

3,066

Recruited

13,430,000+

Dr. William Curry

Massachusetts General Hospital

Chief Medical Officer

MD from Harvard Medical School

Dr. Anne Klibanski

Massachusetts General Hospital

Chief Executive Officer since 2019

MD from Harvard Medical School

University of Colorado, Denver

Lead Sponsor

Trials

1,842

Recruited

3,028,000+

Aviva Abosch

University of Colorado, Denver

Chief Medical Officer since 2019

MD

Uday B. Kompella

University of Colorado, Denver

Chief Executive Officer since 2015

PhD in Pharmaceutical Sciences

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+

Dr. Douglas R. Lowy

National Cancer Institute (NCI)

Chief Executive Officer since 2023

MD from New York University School of Medicine

Dr. Monica Bertagnolli

National Cancer Institute (NCI)

Chief Medical Officer since 2022

MD from Harvard Medical School

Findings from Research

In a clinical trial involving 179 people living with HIV/AIDS, varenicline significantly increased smoking cessation rates at Week 12 compared to placebo, with 28.1% of participants quitting versus 12.1%.

Varenicline was found to be safe, with no significant differences in treatment-related side effects or adverse events compared to placebo, making it a viable option for short-term smoking cessation in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. Ashare, RL., Thompson, M., Serrano, K., et al.[2023]

In a study involving 248 people living with HIV, varenicline combined with counseling significantly increased the rate of smoking cessation compared to placebo, with 15% of participants in the varenicline group achieving continuous abstinence from weeks 9 to 48.

The safety profile of varenicline was favorable, showing a lower incidence of depression in the varenicline group (2%) compared to the placebo group (10%), indicating that varenicline is a safe and effective option for smoking cessation in this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. Mercié, P., Arsandaux, J., Katlama, C., et al.[2018]

In a study of 179 people living with HIV/AIDS, quitting smoking did not negatively impact adherence to anti-retroviral therapy (ART), which remained above 98% for all participants.

Participants who successfully quit smoking reported significant reductions in depression and anxiety symptoms, along with increased life satisfaction, suggesting that smoking cessation can have positive psychological effects for individuals with HIV/AIDS.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Improved clinical outcomes among persons with HIV who quit smoking. Lubitz, SF., Flitter, A., Ashare, RL., et al.[2021]

In a pilot study involving 36 HIV-infected smokers, varenicline was found to be safe and effective for smoking cessation, with a 42% rate of verified continuous abstinence over 4 weeks.

The treatment did not adversely affect HIV viral load, and CD4 counts increased significantly, indicating that varenicline can be a viable option for smoking cessation in this population, despite common side effects like nausea.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. Cui, Q., Robinson, L., Elston, D., et al.[2021]

In a randomized controlled trial, varenicline (Chantix) demonstrated a higher abstinence rate from smoking after one year compared to both bupropion SR (Zyban) and a placebo, indicating its efficacy in treating tobacco dependence.

Despite its effectiveness, varenicline has been associated with serious neuropsychiatric side effects, highlighting the importance of discussing potential risks and benefits with patients considering this treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of nicotine dependence with Chantix (varenicline). Rankin, KV., Jones, DL.[2015]

In a review of ten randomized controlled trials involving 3091 participants, varenicline did not show a significant increase in overall psychiatric disorders compared to placebo, with an incidence of 10.7% in the varenicline group versus 9.7% in the placebo group.

While varenicline was associated with a higher incidence of sleep disorders, there were no reported cases of suicidal ideation or behavior in the analyzed studies, suggesting that varenicline is generally safe for smokers without current psychiatric conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Tonstad, S., Davies, S., Flammer, M., et al.[2022]

Varenicline, when used for smoking cessation in HIV-infected individuals, has a safety profile similar to that observed in non-HIV smokers, with common side effects including nausea and sleep problems, but no significant cardiovascular issues reported.

Preliminary results indicate that varenicline is more effective than nicotine replacement therapy (NRT) for promoting smoking abstinence, with a confirmed abstinence rate of 25.6% in the varenicline group compared to 11.8% in the NRT group, suggesting that varenicline could be a preferred treatment option for this population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of varenicline among smokers enrolled in the lung HIV study. Ferketich, AK., Diaz, P., Browning, KK., et al.[2021]

References

1. Ireland pubmed.ncbi.nlm.nih.gov

Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV. [2023]

2. Netherlands pubmed.ncbi.nlm.nih.gov

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. [2018]

3. England pubmed.ncbi.nlm.nih.gov

Improved clinical outcomes among persons with HIV who quit smoking. [2021]

4. England pubmed.ncbi.nlm.nih.gov

Effects of varenicline on abstinence and smoking reward following a programmed lapse. [2021]

5. United States pubmed.ncbi.nlm.nih.gov

Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. [2021]

6. United States pubmed.ncbi.nlm.nih.gov

Treatment of nicotine dependence with Chantix (varenicline). [2015]

7. England pubmed.ncbi.nlm.nih.gov

Varenicline in smoking cessation. [2017]

8. New Zealand pubmed.ncbi.nlm.nih.gov

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. [2022]

9. England pubmed.ncbi.nlm.nih.gov

Safety of varenicline among smokers enrolled in the lung HIV study. [2021]